Quantcast

[Spotlight] GOLD 2019: a new way forward

Research paper by MeiLan K Han

Indexed on: 23 Dec '18Published on: 23 Nov '18Published in: The Lancet Respiratory Medicine



Abstract

In the past year there has been an explosion of information from clinical trials in chronic obstructive pulmonary disease (COPD), helping us to understand the potential role of combination inhaled therapies, both relative to each other and in particular patient subgroups. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) scientific committee is also accumulating evidence on the role that biomarkers, such as eosinophils, might have in the identification of patients most likely to benefit from inhaled corticosteroids.